retatrutide clinical trial results 2024 Lilly's shows 28% weight loss, but increased side effects Retatrutide—A Game Changer in Obesity

Other Key Findings Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration Discontinuation rate: About 10% of participants stopped due to side effects, comparable to tirzepatide and semaglutide Study limitation: The Phase 2 trial was only 48 weeks long

Our membership program gives you discounted per-service pricing across the menu, priority booking, and early access to new treatments and events

S.DorairajS

Peptides have become the latest obsession on Instagram, TikTok, and YouTube, where influencers rave about injectable stacks that promise fat loss, faster recovery, better sleep, and glowing skin

May 1st, 2025: May 2025 JPML Update The Ozempic multidistrict litigation (MDL) continues to grow, with 124 new cases added over the past month

release the pinch after needle insertion [10]